Yıl: 2022 Cilt: 64 Sayı: 4 Sayfa Aralığı: 781 - 786 Metin Dili: İngilizce DOI: 10.24953/turkjped.2020.3900 İndeks Tarihi: 15-12-2022

AA amyloidosis presenting with acute kidney injury, curable or not?

Öz:
Background. Amyloidosis is a group of disorders with extracellular accumulation of autologous fibrillary insoluble proteins in various tissues and organs such as the kidneys, liver, spleen, heart and gastrointestinal tract leading to impairment of normal organ function. Childhood amyloidosis is an exceedingly rare entity mainly caused by familial Mediterranean fever (FMF) and the other autoinflammatory diseases such as mevalonate kinase deficiency (MKD). Case. A 16-year-old male was referred to pediatric nephrology for coincidentally discovered proteinuria. He had no significant findings on physical examination except for urochromic color. He had nephrotic range proteinuria with 109 mg/m2/h and serum creatinine was 1.35 mg/dl. Kidney biopsy was performed because of nephrotic range proteinuria with acute kidney injury. In hematoxylin-eosin-stained tissue sections, amyloid was suggested as extracellular amorphous material that is lightly eosinophilic in the glomeruli. Diagnosis was confirmed by Congo red positivity, with apple-green birefringence under polarized light. MEFV gene mutation was negative and a compound heterozygote mutation found in mevalonate kinase gene. A 6-monthtrial of colchicine, enalapril, and losartan combination was not successful; Canakinumab was started thereafter. Proteinuria and creatinine decreased to 7 mg/m2/h and 0.6 mg/dl respectively 4 years after treatment. Conclusions. Amyloidosis should be considered especially in children presenting with proteinuria and with a history of recurrent fever. This report also emphasizes the efficacy of canakinumab to prevent or decelerate chronic renal failure in these patients although it does not reduce tissue deposition in long-term use.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık
  • 1. Bilginer Y, Akpolat T, Ozen S. Renal amyloidosis in children. Pediatr Nephrol 2011; 26: 1215-1227. https://doi.org/10.1007/s00467-011-1797-x
  • 2. Favier LA, Schulert GS. Mevalonate kinase deficiency: current perspectives. Appl Clin Genet 2016; 9: 101-110. https://doi.org/10.2147/TACG.S93933
  • 3. Perfetto F, Moggi-Pignone A, Livi R, Tempestini A, Bergesio F, Matucci-Cerinic M. Systemic amyloidosis: a challenge for the rheumatologist. Nat Rev Rheumatol 2010; 6: 417-429. https://doi.org/10.1038/nrrheum.2010.84
  • 4. Real de Asúa D, Costa R, Galván JM, Filigheddu MT, Trujillo D, Cadiñanos J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol 2014; 6: 369-377. https://doi.org/10.2147/CLEP.S39981
  • 5. Lachmann HJ, Goodman HJB, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361-2371. https://doi.org/10.1056/NEJMoa070265
  • 6. van der Hilst JCH, Simon A, Drenth JPH. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005; 5: 87-98. https://doi.org/10.1007/s10238-005-0071-6
  • 7. Ozdogan H, Ugurlu S. Canakinumab for the treatment of familial Mediterranean fever. Expert Rev Clin Immunol 2017; 13: 393-404. https://doi.org/10.1080/1744666X.2017.1313116
  • 8. Durel C-A, Aouba A, Bienvenu B, et al. Observational study of a French and Belgian multicenter cohort of 23 patients diagnosed in adulthood with mevalonate kinase deficiency. Medicine (Baltimore) 2016; 95: e3027. https://doi.org/10.1097/MD.0000000000003027
  • 9. Ozen S, Kuemmerle-Deschner JB, Cimaz R, et al. International retrospective chart review of treatment patterns in severe familial mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, and mevalonate kinase deficiency/ hyperimmunoglobulinemia D syndrome. Arthritis Care Res (Hoboken) 2017; 69: 578-586. https://doi.org/10.1002/acr.23120
  • 10. Grateau G, Jéru I, Rouaghe S, et al. Amyloidosis and auto-inflammatory syndromes. Curr Drug Targets Inflamm Allergy 2005; 4: 57-65. https://doi.org/10.2174/1568010053622786
  • 11. Samuels J, Ozen S. Familial Mediterranean fever and the other autoinflammatory syndromes: evaluation of the patient with recurrent fever. Curr Opin Rheumatol 2006; 18: 108-117. https://doi.org/10.1097/01.bor.0000198006.65697.5b
  • 12. Goldbach-Mansky R, Kastner DL. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J Allergy Clin Immunol 2009; 124: 1141-1149; quiz 1150-1151. https://doi.org/10.1016/j.jaci.2009.11.016
  • 13. Rodrigues F, Philit J-B, Giurgea I, et al. AA amyloidosis revealing mevalonate kinase deficiency: a report of 20 cases including two new French cases and a comprehensive review of literature. Semin Arthritis Rheum 2020; 50: 1370-1373. https://doi.org/10.1016/j.semarthrit.2020.03.005
  • 14. Boursier G, Rittore C, Milhavet F, Cuisset L, Touitou I. Mevalonate kinase-associated diseases: hunting for phenotype-genotype correlation. J Clin Med 2021; 10: 1552. https://doi.org/10.3390/jcm10081552
  • 15. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358: 24-29. https://doi.org/10.1016/s0140-6736(00)05252-1
  • 16. Topaloglu R, Batu ED, Orhan D, Ozen S, Besbas N. Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol 2016; 31: 633-640. https://doi.org/10.1007/s00467-015-3249-5
  • 17. Taşdemir M, Yılmaz S, Baba ZF, Bilge I. A rare cause of AA amyloidosis and end-stage kidney failure: Answers. Pediatr Nephrol 2019; 34: 1537-1539. https://doi.org/10.1007/s00467-018-4153-6
  • 18. Yildirim T, Yilmaz R, Saglam A, Uzerk-Kibar M, Jabrayilov J, Erdem Y. Baseline renal functions predict the effect of canakinumab on regression of proteinuria in patients with familial Mediterranean fever. Nefrologia (Engl Ed) 2021: S0211-6995(21)00024-2. https://doi.org/10.1016/j.nefro.2020.11.011
APA Uysal B, Aytac Vuruskan B (2022). AA amyloidosis presenting with acute kidney injury, curable or not?. , 781 - 786. 10.24953/turkjped.2020.3900
Chicago Uysal Berfin,Aytac Vuruskan Berna AA amyloidosis presenting with acute kidney injury, curable or not?. (2022): 781 - 786. 10.24953/turkjped.2020.3900
MLA Uysal Berfin,Aytac Vuruskan Berna AA amyloidosis presenting with acute kidney injury, curable or not?. , 2022, ss.781 - 786. 10.24953/turkjped.2020.3900
AMA Uysal B,Aytac Vuruskan B AA amyloidosis presenting with acute kidney injury, curable or not?. . 2022; 781 - 786. 10.24953/turkjped.2020.3900
Vancouver Uysal B,Aytac Vuruskan B AA amyloidosis presenting with acute kidney injury, curable or not?. . 2022; 781 - 786. 10.24953/turkjped.2020.3900
IEEE Uysal B,Aytac Vuruskan B "AA amyloidosis presenting with acute kidney injury, curable or not?." , ss.781 - 786, 2022. 10.24953/turkjped.2020.3900
ISNAD Uysal, Berfin - Aytac Vuruskan, Berna. "AA amyloidosis presenting with acute kidney injury, curable or not?". (2022), 781-786. https://doi.org/10.24953/turkjped.2020.3900
APA Uysal B, Aytac Vuruskan B (2022). AA amyloidosis presenting with acute kidney injury, curable or not?. Turkish Journal of Pediatrics, 64(4), 781 - 786. 10.24953/turkjped.2020.3900
Chicago Uysal Berfin,Aytac Vuruskan Berna AA amyloidosis presenting with acute kidney injury, curable or not?. Turkish Journal of Pediatrics 64, no.4 (2022): 781 - 786. 10.24953/turkjped.2020.3900
MLA Uysal Berfin,Aytac Vuruskan Berna AA amyloidosis presenting with acute kidney injury, curable or not?. Turkish Journal of Pediatrics, vol.64, no.4, 2022, ss.781 - 786. 10.24953/turkjped.2020.3900
AMA Uysal B,Aytac Vuruskan B AA amyloidosis presenting with acute kidney injury, curable or not?. Turkish Journal of Pediatrics. 2022; 64(4): 781 - 786. 10.24953/turkjped.2020.3900
Vancouver Uysal B,Aytac Vuruskan B AA amyloidosis presenting with acute kidney injury, curable or not?. Turkish Journal of Pediatrics. 2022; 64(4): 781 - 786. 10.24953/turkjped.2020.3900
IEEE Uysal B,Aytac Vuruskan B "AA amyloidosis presenting with acute kidney injury, curable or not?." Turkish Journal of Pediatrics, 64, ss.781 - 786, 2022. 10.24953/turkjped.2020.3900
ISNAD Uysal, Berfin - Aytac Vuruskan, Berna. "AA amyloidosis presenting with acute kidney injury, curable or not?". Turkish Journal of Pediatrics 64/4 (2022), 781-786. https://doi.org/10.24953/turkjped.2020.3900